Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations

Patricia B Mory, Felipe Crispim, Maria Beatriz S Freire, João Eduardo N Salles, Cynthia M Valério, Amelio F Godoy-Matos, Sérgio A Dib and Regina S Moises

Division of Endocrinology, Paulista School of Medicine, Universidade Federal de São Paulo, Rua Pedro de Toledo, 781 - 12 andar, 04039-032 São Paulo, São Paulo, Brazil, 1Faculdade de Medicina de Jundiaí, Jundiaí, São Paulo, Brazil, 2Faculdade de Ciências Médicas, Santa Casa de São Paulo, São Paulo, São Paulo, Brazil and 3Instituto Estadual de Diabetes e Endocrinologia, Rio de Janeiro, Rio de Janeiro, Brazil

(Correspondence should be addressed to R S Moises; Email: rmoises@unifesp.br)

Abstract

Objective: Mutations in LMNA have been linked to diverse disorders called laminopathies, which display heterogeneous phenotypes and include diseases affecting muscles, axonal neurons, progeroid syndromes, and lipodystrophies. Among the lipodystrophies, LMNA mutations have been reported most frequently in patients with familial partial lipodystrophy (FPLD) of the Dunnigan variety; however, phenotypic heterogeneity in the pattern of body fat loss has been observed. In this study, we searched for LMNA mutations in patients with various forms of lipodystrophy.

Design and methods: We studied 21 unrelated individuals with lipodystrophy. Subjects underwent a complete clinical evaluation and were classified as typical FPLD, atypical partial lipodystrophy, or generalized lipodystrophy. Molecular analysis of LMNA gene, analysis of body fat by dual-energy X-ray absorptiometry, and biochemical measurements were performed.

Results: All patients with typical FPLD were found to carry LMNA mutations: seven patients harbored the heterozygous p.R482W (c.1444C>T), two patients harbored the p.R482Q (c.1445G>A), and two individuals harbored the novel heterozygous variant p.N466D (c.1396A>G), all in exon 8. Also, a homozygous p.R584H (c.1751 G>A) mutation in exon 11 was found. Among patients with atypical partial lipodystrophy, two of them were found to have LMNA mutations: a novel heterozygous variant p.N466D (c.1396A>G) in exon 8 and a heterozygous substitution p.R349W (c.1045C>T) in exon 6. Among patients with generalized lipodystrophy, only one harbored LMNA mutation, a heterozygous p.T10I (c.29C>T) in exon 1.

Conclusions: We have identified LMNA mutations in phenotypically diverse lipodystrophies. Also, our study broadens the spectrum of LMNA mutations in lipodystrophy.

European Journal of Endocrinology 167 423–431

Introduction

Lamin A/C gene (LMNA), which encodes type A lamins, is mapped to chromosome 1q21–22 and contains 12 exons (1). Through alternative splicing, this gene produces two major protein isoforms, lamin A and lamin C, that polymerize with type B lamins to form the nuclear lamina, a complex meshwork of proteins underlying the inner nuclear membrane. Besides the main function of providing structural scaffolding for the cell nucleus, the nuclear lamina also has a role in chromatin organization, connection between nucleus and cytoplasm, gene transcription, and mitosis (2). Mutations in LMNA have been linked to diverse disorders called laminopathies, which display heterogeneous phenotypes and include diseases affecting muscle tissues, axonal neurons, rare progeroid syndromes, and lipodystrophies (3, 4, 5, 6, 7, 8).

Lipodystrophies are a group of clinically heterogeneous disorders characterized by localized or generalized loss of adipose tissue. Metabolic complications such as insulin resistance, impaired glucose tolerance, dyslipidemia, and hepatic steatosis are generally present in affected patients and their severity is determined by the extent of fat loss (9, 10). Among the lipodystrophies, LMNA mutations have been reported most frequently in patients with familial partial lipodystrophy (FPLD) of the Dunnigan variety, an autosomal dominant condition characterized by gradual loss of adipose tissue from the extremities and trunk starting at the puberty. However, phenotypic heterogeneity in the pattern of body fat loss has been observed among the laminopathies (11, 12, 13, 14, 15, 16, 17). Therefore, in this study, we searched for LMNA mutations in patients with various forms of lipodystrophy.
Materials and methods

The study population comprised 21 unrelated individuals (20 females and one male, aged 17- to 64-years old) with lipodystrophy. Subjects underwent a complete clinical evaluation and were classified as typical FPLD \((n=12)\), atypical partial lipodystrophy \((n=7)\), or generalized lipodystrophy \((n=2)\) based on the clinical criteria. Typical FPLD was characterized by progressive postpubertal loss of adipose tissue in limbs, abdomen, and trunk giving rise to appearance of increased muscularity. These patients may develop an excess of fat in face, neck, and supraclavicular region. The phenotype was classified as atypical partial lipodystrophy when this classical phenotype was not accomplished: patients demonstrated a less severe loss of adipose tissue, with the lipoatrophy being more evident in the legs. Patients with generalized lipodystrophy noted loss of fat during childhood or adolescence. Individuals receiving antiretroviral therapy were excluded.

Blood was collected after a 12-h overnight fast for DNA extraction and analysis of plasma glucose and lipoproteins.

Diagnosis of diabetes mellitus was based on fasting plasma glucose \(\geq 126\) mg/dl or use of antidiabetic agents \((18)\). Dyslipidemia was diagnosed when total cholesterol was \(\geq 200\) mg/dl, triglycerides was \(\geq 150\) mg/dl, or HDL-cholesterol level was \(< 40\) mg/dl in men and \(< 50\) mg/dl in women or treatment with lipid-lowering drugs \((19)\). Hypertension was defined as blood pressure \(\geq 140/90\) mmHg or on antihypertensive medication \((20)\). One hundred chromosomes from 50 unrelated nondiabetic individuals (fasting plasma glucose \(< 100\) mg/dl) were used as controls.

Molecular analysis of LMNA gene

DNA was extracted from peripheral blood leukocytes using a commercial kit (Gentra Puregene Blood Kit; Qiagen). Exons 1–12 and the intron–exon boundaries of LMNA gene were amplified by PCR using 14 pairs of primers. The PCR products were directly sequenced with the use of Big Dye Terminator Cycle Sequencing Reaction Kit version 3.1 and analyzed on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). We used \textit{in silico} bioinformatic tools, Polyphen \((21)\) and SIFT \((22)\), to predict the potential pathogenic effect of novel missense variants.

Analysis of total and segmental body fat

Dual-energy X-ray absorptiometry (DEXA) was used to evaluate whole-body and regional fat with the Hologic device (model QDR-4500A; Hologic, Inc., Bedford, MA, USA). Reference values were determined in healthy subjects matched for sex, age, and BMI. Each female patient was matched with a subject based on sex, age (within 3 years), and BMI (within \(3\) kg/m\(^2\)). For the male patient, four subjects were matched based on sex, age (within 1 year), and BMI (within \(3\) kg/m\(^2\)).

Biochemical measurements

Plasma glucose was determined by the glucose-oxidase method and insulin by chemoluminescence assay. Cholesterol contents of lipoprotein fractions and triglycerides were measured enzymatically. Leptin and adiponectin concentrations were measured by ELISA (Linco Research, St Charles, MI, USA). This study was approved by the Ethics Committee of Escola Paulista de Medicina, Universidade Federal de São Paulo, and all participants were informed about the aims of the study and gave their written consent.

![Figure 1](https://www.eje-online.org) Whole and regional body fat in lipodystrophic patients carrying LMNA mutations. The box displays the median and interquartile range (25th–75th percentile) and the whiskers display the 10th and 90th values for age-, sex-, and BMI-matched control individuals. Phenotypes of patients are symbolized as follows: open circle, typical FPLD; open square, atypical partial lipodystrophy; and closed triangle, generalized lipodystrophy.
Results

Among the 21 patients with lipodystrophy who were screened, LMNA mutations were found in 15 of them. Whole-body and regional fat measurements showed that, compared with normal age-, sex-, and BMI-matched controls, women with typical FPLD had reduced percentage of fat in arms and legs, while the patient P13 with atypical partial lipodystrophy had reduced fat only in the legs. As expected, the patient with generalized lipodystrophy had markedly reduced percentage of fat on all sites examined. The male patient P14 showed reduced percentage of fat only in the legs (Fig. 1).

Typical FPLD

Twelve patients (P1–P12), all female, aged 17–64 years, and from unrelated families with FPLD were studied. All of them were found to carry LMNA mutations: seven patients harbored the heterozygous p.R482W (c.1444C>T) variation in exon 8, two patients harbored the p.R482Q (c.1445G>A) variation, two individuals (patients P1 and P11) harbored the novel heterozygous variant p.N466D (c.1396A>G) also in exon 8, and one patient (P12) harbored the homozygous p.R584H (c.1751G>A) variation in exon 11. The novel variant p.N466D was not seen in 100 normal chromosomes and was predicted to be possibly damaging by PolyPhen and tolerated by SIFT.

Patient P1, a 22-year-old female, had insulin-requiring diabetes diagnosed at age 17. She also had hypertension and hypertriglyceridemia since age 18. Physical examination showed the typical fat loss mentioned earlier (Fig. 2). Acanthosis nigricans was present in the cervical region and axillae. Hypertrophy of the calves was also observed. Her mother, also a carrier of the p.N466D variant, had diabetes diagnosed at age 24 complicated with coronaropathy, nephropathy, and neuropathy. She died at the age of 44 years due to myocardial infarction. Patient P11 is a 19-year-old female, apparently not related to P1, with diabetes and hypertension diagnosed at age 18. Loss of subcutaneous fat was first noticed at age 10. Physical examination showed lipodystrophy of the limbs and trunk and prominent muscles in her legs. Her father, a mutation carrier, had dyslipidemia and impaired fasting glucose. Patient P12 is a 26-year-old female with moderate decrease in subcutaneous fat on limbs and trunk, prominent veins in legs, and acanthosis nigricans in the axillae (Fig. 3). The only plasma lipid abnormality detected was low HDL-cholesterol (46 mg/dl). Hypertension was not present. An oral glucose tolerance test was performed and showed normal glucose tolerance. A homozygous p.R584H (c.1751 G>A) in exon 11 was found. Both of her parents, first-degree cousins, were heterozygous for this mutation. Her father apparently did not have the phenotypic abnormalities suggestive of lipodystrophy, but a clinical evaluation could not be performed. His lipid profile showed mild dyslipidemia (HDL-cholesterol 35 mg/dl, LDL-cholesterol 142 mg/dl, and triglycerides 58 mg/dl) with normal fasting glucose. Clinical examination of her mother showed no evidence of lipodystrophy or acanthosis nigricans. Vitiligo lesions were present in the face, trunk, and limbs (Fig. 3). Dyslipidemia was present (total cholesterol 285 mg/dl, HDL-cholesterol 58 mg/dl, LDL-cholesterol 189 mg/dl, and triglycerides 160 mg/dl) with normal glucose tolerance (fasting plasma glucose 95 mg/dl and 2-h post-glucose load 118 mg/dl).

Atypical partial lipodystrophy

Among the individuals with atypical partial lipodystrophy, two of them were found to have mutations in
P13 is a 57-year-old woman who has noticed decreased subcutaneous fat on limbs at age 20. Dyslipidemia and hypertension were diagnosed at age 36 and type 2 diabetes at age 43. Physical examination showed moderate decrease in fat in limbs and an increase in upper trunk fat (Fig. 4). She had no acanthosis nigricans. As chronic complications of diabetes, she developed retinopathy, nephropathy, and peripheral neuropathy. A novel heterozygous p.R582C mutation (c.1744 C>T) in exon 11 was found. This variant was not found in 100 normal chromosomes. PolyPhen and SIFT analysis predicts that p.R582C is probably damaging.

Patient P14 is an 18-year-old boy with hypertriglyceridemia diagnosed at age 12 during investigation for short stature. Diabetes, hypertension, and acanthosis nigricans were absent. Examination at age 18 revealed loss of subcutaneous fat in limbs including dorsal and palmar aspects of hand and feet and micrognathia (Fig. 5). The age of onset of fat loss was undetermined. Height was 160 cm (below 5th percentile, both parents were between percentiles 10 and 25). Features of premature ageing such as graying hair, partial alopecia, high-pitched voice, skin atrophy over the hands and feet, bone deformations, and skin pigmentation were absent. Neurological examination showed no evidence of muscle weakness or atrophy, although complaints of myalgia were present. Elevated creatinine phosphokinase (CPK) levels (252 U/l) were observed. Noninvasive cardiac investigation (electrocardiography, transthoracic echocardiography, and 24-h Holter monitoring) was performed and revealed no abnormalities. A heterozygous substitution from arginine for tryptophan at residue 349 (c.1045C>T, p.R349W) in exon 6 was found. Both of his parents were negative for this mutation, indicating that it is a de novo mutation. Figure 6 shows the genealogical trees of families carrying new LMNA mutations demonstrating the familial segregation of the disease.

**Generalized lipodystrophy**

LMNA mutation was found in only one patient (P15). Patient P15 with pubertal-onset generalized lipodystrophy and severe insulin resistance was previously described (16). The heterozygous p.T10I (c.29C>T, p.R349W) mutation in exon 6 was found in the proband but was absent in both of her parents. Table 1 shows the main features of patients P1, P11, P12, P13, and P14, and Fig. 7 shows the localization of LMNA mutations identified in the study population.

**Discussion**

All our patients with typical FPLD, except the three cases, were found to carry heterozygous mutations affecting codon 482 in exon 8. This finding confirms previous observations that this residue is a mutational...
hot spot for FPLD (11, 23, 24). A novel mutation (p.N466D), also located in exon 8, was found in two nonrelated patients with typical FPLD. This variant has been already reported in the Leiden Muscular Dystrophy database (http://www.dmd.nl/nmdb/variants.php?action=Zsearch_unique&select_db=LMNA); however, it has not been published elsewhere and there is no clinical information about it. This variant is likely to be pathogenic, as it was absent in 100 control chromosomes, occurs in an amino acid conserved through different species, and segregated with the disease. The two patients affected by this mutation come from distinct states of Brazil and are apparently unrelated, so it is assumed that the mutation has arisen as a separate event. However, additional analysis would be needed to further evaluate a potential founder effect in these families. Another DNA variation we found in a patient with typical partial lipodystrophy was a homozygous p.R584H mutation in exon 11. This patient had only mild metabolic abnormality (low HDL-cholesterol levels and no diabetes or hypertension). The proband’s parents were heterozygous for the mutation and had no phenotypic alterations suggestive of lipodystrophy, indicating a recessive trait. Interestingly, two previous reports describing patients with FPLD carriers of this mutation were in heterozygous state and the affected patients showed metabolic complications of lipodystrophy such as diabetes, dyslipidemia, and hepatic steatosis (24, 25). To the best of our knowledge, there is only one previous report of a homozygous LMNA mutation associated with a lipodystrophic phenotype (26). Le Dour et al. identified a frameshift mutation and, in contrast to our data, the affected individuals presented a severe lipodystrophy with metabolic alterations. The heterozygous relatives showed either a partial phenotype or were asymptomatic indicating a codominant transmission of the disease with incomplete penetrance in heterozygous subjects. The reasons for these discrepancies are not clear. We can speculate that additional genetic variants and/or intrauterine and postnatal environmental factors might affect the disease expression. Also, the fact that our patient is still young (26 years old) and lean (BMI: 19 kg/m²) could explain her attenuated phenotype. These observations show that lipodystrophy associated with LMNA mutations in exon 11 can be detected in patients presenting a broad clinical spectrum.

Among the patients with atypical partial lipodystrophy, LMNA mutation was found only in two patients. One patient harbors a novel heterozygous CGC>TGC transition at codon 582 (exon 11) leading to an arginine to cysteine substitution (p.R582C). Speckman et al. (23) previously reported a different mutation in the same codon (p.R582H) in a patient with partial lipodystrophy and a detailed evaluation of body fat distribution with anthropometry and magnetic resonance imaging was performed (11). Similarly, as described by these authors, our patient presented a fat loss from gluteal and truncal regions less pronounced than in patients with the typical phenotype. Mutations in exon 11 affect the globular domain specific to lamin A isoform, while mutations in exon 8 affect the globular domain of both splice forms, lamin A and lamin C. Garg et al. (11) observed a milder lipodystrophy as well as less severe metabolic complications in patients with a mutation in exon 11 of LMNA compared with others with mutations in exon 8. Our findings are in agreement with these observations.

Another patient with atypical lipodystrophy harboring a LMNA mutation was a male subject presenting with fat loss in limbs also involving the palms and soles (mechanical fat loss). This pattern of fat loss drew the attention and permitted the clinical diagnosis of lipodystrophy, as in men this condition is frequently unrecognized. In this patient, the lipodystrophy was not associated with diabetes or hypertension but only with dyslipidemia. Previous reports show that men with FPLD have lower prevalence of metabolic complications of insulin resistance than women (24, 27). He was
found to carry a heterozygous substitution in a highly conserved residue localized in exon 6 (p.R349W), which affects the α-helical rod domain of both lamin A and lamin C. This variant was previously reported in a patient with partial lipodystrophy, mild myopathy, and dilated cardiomyopathy (28). There are other previous reports of LMNA amino-terminal head and α-helical rod domain mutations causing overlapping phenotype of partial lipodystrophy and cardiomyopathy or cardiac conduction defects (29, 30). Also, at codon 349, another variant (p.R349L) was associated with a severe familial form of isolated dilated cardiomyopathy (31).

In view of these findings, we performed cardiac evaluation of our patient with transthoracic echocardiography and 24-h Holter monitoring, and both were normal. Our observation of this patient shows that p. R349W mutation can, at least at presentation, be associated with lipodystrophy without cardiac abnormality. However, as the patient is still young and in some cases the onset of cardiac manifestations occurred at later ages, a close follow-up was indicated.

Another alteration found was a T10I change in exon 1 in a patient with generalized lipodystrophy. This variation was previously described by Csoka et al. (32) in

Figure 5 Photograph of P14 with atypical partial lipodystrophy, harboring the heterozygous p.R349W LMNA mutation showing the paucity of subcutaneous fat on limbs including dorsal and palmar aspects of hand and feet, and the presence of micrognathia (A). MR images at the levels of the thigh and abdomen showing markedly reduced subcutaneous fat with preservation of intermuscular and bone marrow fat (B). The patients gave their written consent to the use of their pictures and they understand that complete anonymity cannot be guaranteed.

Figure 6 Genealogical trees of families carrying new LMNA mutations. Filled symbols indicate homozygous subjects, half-filled symbols indicate heterozygous subjects, gray symbols indicate subjects probably affected by lipodystrophy, and unfilled symbols indicate individuals unaffected by lipodystrophy. The text below each individual represents the following: DM, diabetes mellitus; IFG, impaired fasting glucose; NGT, normal glucose tolerance; DLP, dyslipidemia; HBP, hypertension; N, wild-type allele; M, mutant allele.
a patient diagnosed with atypical progeroid syndrome, later reclassified as ‘Seip syndrome’ based on generalized lipoatrophy and metabolic alterations. Complex genotype–phenotype relationships are present in laminopathies, and variability in the lipodystrophy clinical expression in patients, even among family members, with the same mutation has been reported previously (25, 33). Nongenetic factors and/or additional genetic variants may modulate the disease phenotype.

In this study, we found seven different LMNA mutations in patients with various forms of lipodystrophy, most of them (5/7) in region 3’ to the nuclear localization signal sequence (codons 416–423). Hegele using hierarchical cluster analysis for assembling laminopathies according to phenotypic similarity found that LMNA mutations at the 5’ of codon 416 were seen more frequently in laminopathies with cardiac or neurological involvement, and in addition several overlapping syndromes, while mutations at the 3’ of codon 423 are more likely to be associated with simple partial lipodystrophy, progeria syndrome, or mandibuloacral dysplasia (34). Our findings are in agreement with this, as the mutations found at the 3’ to the nuclear localization signal were in patients with simple partial lipodystrophy. The two mutations found at the 5’ to the nuclear localization signal were in

Table 1 Characteristics of patients P1, P11, P12, P13, and P14.

<table>
<thead>
<tr>
<th></th>
<th>P1</th>
<th>P11</th>
<th>P12</th>
<th>P13</th>
<th>P14</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>M</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>22</td>
<td>19</td>
<td>26</td>
<td>57</td>
<td>18</td>
</tr>
<tr>
<td><strong>Lipodystrophy classification</strong></td>
<td>Typical partial</td>
<td>Typical partial</td>
<td>Typical partial</td>
<td>Atypical partial</td>
<td>Atypical partial</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>26</td>
<td>28</td>
<td>19</td>
<td>30</td>
<td>20</td>
</tr>
<tr>
<td><strong>Age at diabetes diagnosis (years)</strong></td>
<td>17</td>
<td>18</td>
<td>—</td>
<td>43</td>
<td>—</td>
</tr>
<tr>
<td><strong>Antidiabetic medications</strong></td>
<td>MTF, TZD, insulin 0.5 U/kg per day</td>
<td>MTF —</td>
<td>TZD, insulin 1.4 U/kg per day</td>
<td>MTF, TZD</td>
<td></td>
</tr>
<tr>
<td><strong>Acanthosis nigricans</strong></td>
<td>+</td>
<td>+</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Antihypertensive medications</strong></td>
<td>ACE inhibitor, HCTZ</td>
<td>ACE inhibitor —</td>
<td>ACE inhibitor, furosemide, CCB</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td><strong>Lipid lowering medications</strong></td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Other features</strong></td>
<td>Thyroid nodule —</td>
<td>Thyroid node —</td>
<td>Statin Ankylosis, depression, thyroiditis Myalgia</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HbA1c (%)</strong></td>
<td>11.7</td>
<td>6.9</td>
<td>ND</td>
<td>9.6</td>
<td>5.9</td>
</tr>
<tr>
<td><strong>HOMA-IR</strong></td>
<td>ND</td>
<td>31.1</td>
<td>1.3</td>
<td>ND</td>
<td>5.9</td>
</tr>
<tr>
<td><strong>Adiponectin (ng/ml)</strong></td>
<td>4.8</td>
<td>4.5</td>
<td>5.2</td>
<td>18.0</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td><strong>Leptin (µg/ml)</strong></td>
<td>6.0</td>
<td>4.6</td>
<td>1.1</td>
<td>32.9</td>
<td>2.2</td>
</tr>
<tr>
<td><strong>Total-cholesterol (mg/dl)</strong></td>
<td>155</td>
<td>185</td>
<td>145</td>
<td>170</td>
<td>150</td>
</tr>
<tr>
<td><strong>HDL-cholesterol (mg/dl)</strong></td>
<td>29</td>
<td>41</td>
<td>46</td>
<td>42</td>
<td>17</td>
</tr>
<tr>
<td><strong>LDL-cholesterol (mg/dl)</strong></td>
<td>ND</td>
<td>113</td>
<td>61</td>
<td>100</td>
<td>91</td>
</tr>
<tr>
<td><strong>Triglycerides (mg/dl)</strong></td>
<td>544</td>
<td>157</td>
<td>125</td>
<td>156</td>
<td>210</td>
</tr>
<tr>
<td><strong>AST (U/l)</strong></td>
<td>15</td>
<td>13</td>
<td>11</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td><strong>ALT (U/l)</strong></td>
<td>27</td>
<td>21</td>
<td>16</td>
<td>17</td>
<td>21</td>
</tr>
<tr>
<td><strong>CPK (U/l)</strong></td>
<td>92</td>
<td>ND</td>
<td>ND</td>
<td>60</td>
<td>252</td>
</tr>
<tr>
<td><strong>Hepatic steatosis</strong></td>
<td>+</td>
<td>ND</td>
<td>—</td>
<td>ND</td>
<td>+</td>
</tr>
<tr>
<td><strong>Total body fat (%)</strong></td>
<td>20.7</td>
<td>14.1</td>
<td>12.1</td>
<td>34.6</td>
<td>14.2</td>
</tr>
<tr>
<td><strong>Trunk fat (%)</strong></td>
<td>23.2</td>
<td>17.3</td>
<td>13.7</td>
<td>43.5</td>
<td>16.7</td>
</tr>
<tr>
<td><strong>Arms fat (%)</strong></td>
<td>19.1</td>
<td>12.6</td>
<td>7.5</td>
<td>34.5</td>
<td>14.3</td>
</tr>
<tr>
<td><strong>Legs fat (%)</strong></td>
<td>16.3</td>
<td>10.7</td>
<td>12.0</td>
<td>20.7</td>
<td>10.9</td>
</tr>
<tr>
<td><strong>Hba1c (%)</strong></td>
<td>11.7</td>
<td>6.9</td>
<td>ND</td>
<td>9.6</td>
<td>5.9</td>
</tr>
<tr>
<td><strong>HOMA-IR</strong></td>
<td>ND</td>
<td>31.1</td>
<td>1.3</td>
<td>ND</td>
<td>5.9</td>
</tr>
<tr>
<td><strong>Adiponectin (ng/ml)</strong></td>
<td>4.8</td>
<td>4.5</td>
<td>5.2</td>
<td>18.0</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td><strong>Leptin (µg/ml)</strong></td>
<td>6.0</td>
<td>4.6</td>
<td>1.1</td>
<td>32.9</td>
<td>2.2</td>
</tr>
<tr>
<td><strong>Total-cholesterol (mg/dl)</strong></td>
<td>155</td>
<td>185</td>
<td>145</td>
<td>170</td>
<td>150</td>
</tr>
<tr>
<td><strong>HDL-cholesterol (mg/dl)</strong></td>
<td>29</td>
<td>41</td>
<td>46</td>
<td>42</td>
<td>17</td>
</tr>
<tr>
<td><strong>LDL-cholesterol (mg/dl)</strong></td>
<td>ND</td>
<td>113</td>
<td>61</td>
<td>100</td>
<td>91</td>
</tr>
<tr>
<td><strong>Triglycerides (mg/dl)</strong></td>
<td>544</td>
<td>157</td>
<td>125</td>
<td>156</td>
<td>210</td>
</tr>
<tr>
<td><strong>AST (U/l)</strong></td>
<td>15</td>
<td>13</td>
<td>11</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td><strong>ALT (U/l)</strong></td>
<td>27</td>
<td>21</td>
<td>16</td>
<td>17</td>
<td>21</td>
</tr>
<tr>
<td><strong>CPK (U/l)</strong></td>
<td>92</td>
<td>ND</td>
<td>ND</td>
<td>60</td>
<td>252</td>
</tr>
<tr>
<td><strong>Hepatic steatosis</strong></td>
<td>+</td>
<td>ND</td>
<td>—</td>
<td>ND</td>
<td>+</td>
</tr>
<tr>
<td><strong>Total body fat (%)</strong></td>
<td>20.7</td>
<td>14.1</td>
<td>12.1</td>
<td>34.6</td>
<td>14.2</td>
</tr>
<tr>
<td><strong>Trunk fat (%)</strong></td>
<td>23.2</td>
<td>17.3</td>
<td>13.7</td>
<td>43.5</td>
<td>16.7</td>
</tr>
<tr>
<td><strong>Arms fat (%)</strong></td>
<td>19.1</td>
<td>12.6</td>
<td>7.5</td>
<td>34.5</td>
<td>14.3</td>
</tr>
<tr>
<td><strong>Legs fat (%)</strong></td>
<td>16.3</td>
<td>10.7</td>
<td>12.0</td>
<td>20.7</td>
<td>10.9</td>
</tr>
</tbody>
</table>

ACE, angiotensin-converting enzyme; CCB, calcium channel blocker; HCTZ, hydrochlorothiazide; MTF, metformin; ND, not determined; TZD, thiazolidinedione.

Figure 7 LMNA mutations identified in the study population and their relation to the gene and protein structure of lamins A and C. Novel mutations are shown in bold.
patients with complex overlapping syndromes. Although no cardiac or neurological involvement was present in the affected subjects, we cannot exclude the possibility that these conditions appear later in life as these patients are still young.

A limitation of our study is that our data only concern LMNA-linked lipodystrophies. Besides LMNA, several other loci (i.e., PPARG, AKT2, CAV1, CIDEC, and PLIN1) have been implicated in the pathogenic basis of lipodystrophic syndromes (35, 36, 37, 38, 39). Therefore, additional sequencing for these loci could be considered in our patients with no LMNA mutations.

In summary, we have identified LMNA mutations in phenotypically diverse, either partial or generalized, lipodystrophies. Also, novel mutations were found, broadening the spectrum of reported genotypes in lipodystrophy, and variable phenotypes associated with previously reported mutations have been identified.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, grant # 07/59297-1).

Acknowledgements
The authors are grateful to the patients and their families for participating in the study and to Dr Amanda O Silveira for patient referral.

References
and Classification of Diabetes Mellitus. Follow-up report on the

19 Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults. Executive Summary of the
Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol In Adults (Adult Treatment Panel III).

20 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,
Izzo JJ Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ &
National Heart, Lung, and Blood Institute Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure & National High Blood Pressure Education

21 Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS &
Speckman RA, Garg A, Du F, Bennett L, Veile R, Arioglu E,
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,
Izzo JJ Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ &
National Heart, Lung, and Blood Institute Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in Adults (Adult Treatment Panel III).

22 Ng PC & Henikoff S. SIFT: predicting amino acid changes
that affect protein function. *Nucleic Acids Research* 2003 **31**
3812–3814. (doi:10.1093/nar/gkg509)

23 Speckman RA, Garg A, Du F, Bennett L, Veile R, Arioglu E,

24 Vigouroux C, Magrê J, Vantyghem MC, Bourrù C, Lascols O,
Shackleton S, Lloyd DJ, Guerci B, Padova G, Valensi P, Grimaldi A,

25 Hegele RA, Cao H, Anderson CM & Hramiak IM. Heterogeneity

26 Le Dour C, Schneebeli S, Bärti F, Parrot E, Jacobsson ML,
Maubert MA, Auclair M, Jeziorowska D, Reznik Y, Bézéat V,
Capeau J, Lascols O & Vigouroux C. A homozygous mutation of
Prelamin-A preventing its farnesylation and maturation leads to a severe lipodystrophic phenotype: new insights into the pathogenicity of nonfarnesylated Prelamin-A. *Journal of Clinical Endocrinology and Metabolism* 2011 **96** E856–E862. (doi:10.1210/jc.2010-2234)


28 van Tintelen JP, Hofstra RM, Katerberg H, Rossenbacker T,
Tiesfeld AC, de Marchie Sarvaa GJ, Wildes AA, van Langen IM,
Nannenberg EA, van der Kooi AJ, Kraak M, van Gelder IC, van

29 Garg A, Speckman RA & Bowcock AM. Multisystem dystrophy
disease due to novel missense mutations in the amino-terminal

30 Subramanyam L, Simha V & Garg A. Overlapping syndrome with
familial partial lipodystrophy. Dunnigan variety and cardiomyopathy

31 Hermida-Prieto M, Monserrat L, Beuchela A, Laredo R,
Soler R, Peteiro J, Rodríguez E, Bouzas B, Alvarez N, Muñiz J &
Crespo-Leiro M. Familial dilated cardiomyopathy and isolated left

32 Csaika AB, Cao H, Summak PJ, Constantinescu D, Schatten GP &

33 Rankin J, Auer-Grunbach M, Bagg W, Colclough K, Nguyen TD,
Fenton-May J, Hattersley A, Hudson J, Jardine P, Josifova D,

34 Hegele RA. LMNA mutation position predicts organ system

35 Agarwal AK & Garg A. A novel heterozygous mutation in
perinatal prolarerated receptor g gene in a patient with

36 George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC,
Soos MA, Murgatroyd PR, Williams RM, Acrini CL, Dunger DB,
Barford D, Uempley AM, Wareham NJ, Davies HA, Schaefer AJ,


38 Rubio-Cabezas O, Purí V, Murano I, Saudek V, Semple RK, Dash S,
Hyden CS, Bottomley W, Vigouroux C, Magré J, Raymond-Barker P,
Murgatroyd PR, Chawla A, Skepper JN, Chatterjee VK, Suliman S,
Patch AM, Agarwal AK, Garg A, Barroso I, Canti S, Czech MP,
Partial lipodystrophy and insulin resistant diabetes in a patient with
a homozygous nonsense mutation in CIDE C. *EMBO Molecular Medicine* 2009 **1** 280–287. (doi:10.1002/emmm.200900037)

39 Gandotra S, Le Dour C, Bottomley W, Cervera P, Girul P, Reznik Y,
Charpentier G, Auclair M, Delépine M, Barroso I, Semple RK,
Lathrop M, Lascols O, Capeau J, ‘O’Rahilly S, Magré J, Savage DB
& Vigouroux C. Perilipin deficiency and autosomal dominant

Received 29 October 2011
Revised version received 9 May 2012
Accepted 14 June 2012

www.eje-online.org